Stockscreener 앱 받기
120.23
13.52%
-18.80
시간 외 거래:
120.24
0.010
+0.01%
전일 마감가:
$139.03
열려 있는:
$139.14
하루 거래량:
2.71M
Relative Volume:
3.49
시가총액:
$7.06B
수익:
$551.35M
순이익/손실:
$-189.33M
주가수익비율:
-36.53
EPS:
-3.2916
순현금흐름:
$-35.09M
1주 성능:
-16.51%
1개월 성능:
-1.17%
6개월 성능:
+20.69%
1년 성능:
+23.71%
1일 변동 폭
$118.64
$139.43
1주일 범위
$118.64
$148.11
52주 변동 폭
$73.16
$148.11
Glaukos Corp Stock (GKOS) Company Profile
명칭
Glaukos Corp
전화
949-367-9600
주소
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corp
|
120.23 | 8.17B | 551.35M | -189.33M | -35.09M | -3.2916 |
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Glaukos Corp Stock (GKOS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-27 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-10-01 | 개시 | Goldman | Buy |
| 2025-05-01 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-12-11 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-12-06 | 개시 | UBS | Buy |
| 2024-12-02 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-05-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-12-21 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-04 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-11-28 | 개시 | Truist | Buy |
| 2023-11-08 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | 개시 | Mizuho | Neutral |
| 2022-12-19 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-12-12 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-10-14 | 재개 | Stephens | Overweight |
| 2022-10-04 | 개시 | Needham | Buy |
| 2022-07-12 | 업그레이드 | Stifel | Hold → Buy |
| 2022-02-03 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2021-11-03 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-07-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-01-29 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | 업그레이드 | Citigroup | Sell → Neutral |
| 2020-12-09 | 개시 | Oppenheimer | Perform |
| 2020-11-17 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2020-06-15 | 개시 | Jefferies | Hold |
| 2020-03-05 | 개시 | Citigroup | Sell |
| 2020-02-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-01-06 | 업그레이드 | Berenberg | Hold → Buy |
| 2019-12-12 | 다운그레이드 | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | 개시 | BTIG Research | Neutral |
| 2018-08-30 | 개시 | Berenberg | Hold |
| 2018-08-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-08-03 | 재확인 | Stifel | Hold |
| 2018-06-21 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-04-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-01 | 재확인 | Cantor Fitzgerald | Buy |
| 2017-03-02 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-01-06 | 업그레이드 | Stifel | Hold → Buy |
| 2016-10-27 | 개시 | Wells Fargo | Outperform |
모두보기
Glaukos Corp 주식(GKOS)의 최신 뉴스
Glaukos slides 8% as investors appear to take profits after a strong run, with recent insider-sale filings adding pressure - Quiver Quantitative
Nvidia To Rally More Than 123%? Here Are 10 Top Analyst Forecasts For Thursday - Sahm
GKOS Maintained by BTIG -- Price Target Raised to $162 - GuruFocus
BTIG raises Glaukos stock price target to $162 on product pipeline - Investing.com
Glaukos director Kliman sells $703,800 in stock By Investing.com - Investing.com Nigeria
Glaukos Corp stock (US3773221029): 52-week high and fresh insider sale stir investor interest - AD HOC NEWS
Glaukos director Kliman sells $703,800 in stock - Investing.com
Director at Glaukos (NYSE: GKOS) exercises options and sells 5,000 shares - Stock Titan
Glaukos stock hits 52-week high at $146.90 By Investing.com - Investing.com Nigeria
Glaukos stock hits 52-week high at $146.90 - Investing.com UK
DNB Asset Management AS Grows Stock Position in Glaukos Corporation $GKOS - MarketBeat
Glaukos Corp stock (US3773221029): eye-care specialist gains attention after FDA approval and strong - AD HOC NEWS
Glaukos (GKOS) price target increased by 12.59% to 154.96 - MSN
Janus Henderson Group (GKOS) discloses 5.35M shares, 9.2% holding - Stock Titan
Glaukos (GKOS) Stock Price, News & Analysis - MarketBeat
Gilbert H. Kliman (GKOS) files Form 144 to sell 5,000 shares - Stock Titan
Glaukos stock (US3773221029): Director sale signals confidence near 52-week highs - AD HOC NEWS
Glaukos director Gilbert H Kliman sells $675,000 of company stock - Investing.com UK
Glaukos director Gilbert H Kliman sells $675,000 of company stock By Investing.com - Investing.com South Africa
TradingKey - TradingKey
Glaukos Corp stock (US3773221029): Insider files Form 144 for 5,000-share sale - AD HOC NEWS
Glaukos Announces Participation in Upcoming Investor Conferences - PharmiWeb.com
How to watch Glaukos at four upcoming investor conferences - Stock Titan
[144] GLAUKOS Corp SEC Filing - Stock Titan
Presbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape | DelveInsight - GlobeNewswire Inc.
Number of shareholders of Glaukos Corp – LS:A14VCK - TradingView
Glaukos Corp stock (US3773221029): Raised 2026 sales guidance lifts medtech profile - AD HOC NEWS
Glaukos wins permanent J-code for Epioxa keratoconus therapy - MSN
Glaukos Corp. Hits New 52-Week High at $145.50, Reflecting Strong Growth - Markets Mojo
Glaukos SVP & CFO Alex Thurman sells $1.4m in shares - Investing.com Australia
Glaukos SVP & CFO Alex Thurman sells $1.4m in shares By Investing.com - Investing.com South Africa
Glaukos president & COO Gilliam sells $2.8m in company stock - Investing.com Australia
Glaukos president & COO Gilliam sells $2.8m in company stock By Investing.com - Investing.com South Africa
Glaukos (GKOS) CFO exercises options and sells 10,000 shares under plan - Stock Titan
GLAUKOS (GKOS) President & COO sells 19,573 shares in open-market trade - Stock Titan
GLAUKOS (GKOS) director Leana Wen sells 1,700 shares, holds 19,739 - Stock Titan
Glaukos Corp Leads Innovation in Chronic Eye Disease Treatment with iDose TR and Epioxa Therapies – 2026 Investor Update - Minichart
Glaukos to present May 2026 investor slide deck highlighting iDose TR, Epioxa launch and 2026 guidance - TradingView
[8-K] GLAUKOS Corp Reports Material Event - Stock Titan
How The Glaukos (GKOS) Narrative Is Shifting With New Guidance And Product Ramp Expectations - Yahoo Finance
UBS Group AG Increases Position in Glaukos Corporation $GKOS - MarketBeat
MSN - MSN
Glaukos (NYSE:GKOS) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Glaukos Corp. Earnings Call Signals Growth Momentum - The Globe and Mail
Glaukos Up Over 19%, On Track for Largest Percent Increase Since December 2023 -- Data Talk - Moomoo
Fidelity Brokerage Services LLC (GKOS) files Form 144 to sell 19,573 shares - Stock Titan
GKOS SWOT Analysis: Key Insights from the 10-Q Filing - GuruFocus
Glaukos Corp (GKOS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.22%
1.41%
자본화:
|
볼륨(24시간):